CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study - COOPER, C.L.; DAVIS, H.L.; MORRIS, M.L.; EFLER, S.M.; ADHAMI, M. AL; KRIEG, A.M.; CAMERON, D.W.; HEATHCOTE, J. (Journal of clinical immunology, 2004)
Keywords: Adjuvants, Immunologic - administration & dosage; Adjuvants, Immunologic - toxicity; Adolescent; Adult; Antibody Formation; Double-Blind Method; Female; Hepatitis B Surface Antigens - administration & dosage; Hepatitis B Surface Antigens - immunology; Hepatitis B Vaccines - administration & dosage; Hepatitis B Vaccines - toxicity; Humans; Immunophenotyping; Male; Membrane Glycoproteins - agonists; Oligodeoxyribonucleotides - administration & dosage; Oligodeoxyribonucleotides - toxicity; Receptors, Cell Surface - agonists; T-Lymphocytes - immunology; T-Lymphocytes, Cytotoxic - immunology; Toll-Like Receptor 9; Toll-Like Receptors; Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - toxicity